PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAngiotensin ii
Angiotensin ii
Giapreza (angiotensin ii) is a protein pharmaceutical. Angiotensin ii was first approved as Giapreza on 2017-12-21. It is used to treat hypotension in the USA. It has been approved in Europe to treat hypotension and shock. It is known to target type-2 angiotensin II receptor, proto-oncogene Mas, potassium channel subfamily K member 3, and type-1 angiotensin II receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
angiotensin iiANDA2025-06-04
giaprezaNew Drug Application2024-11-26
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Angiotensin Ii Acetate, Giapreza, La Jolla Pharma
112196622037-01-06U-3262
92207452034-12-18U-2217, U-2218
100289952034-12-18U-2338
104931242034-12-18U-2679
110969832034-12-18U-3211, U-3212
115595592034-12-18U-3514
95728562031-07-18U-2221
98678632029-12-16U-2231
103354512029-12-16U-2581
105002472029-12-16U-2680, U-2681
105489432029-12-16U-2739, U-2740
ATC Codes
C: Cardiovascular system drugs
C01: Cardiac therapy drugs
C01C: Cardiac stimulants excl. cardiac glycosides
C01CX: Other cardiac stimulants in atc
C01CX09: Angiotensin ii
C09: Agents acting on the renin-angiotensin system
C09C: Angiotensin ii receptor blockers (arbs), plain
C09CA: Angiotensin ii receptor blockers (arbs), plain
C09D: Angiotensin ii receptor blockers (arbs), combinations
C09DA: Angiotensin ii receptor blockers (arbs) and diuretics
C09DB: Angiotensin ii receptor blockers (arbs) and calcium channel blockers
C09DX: Angiotensin ii receptor blockers (arbs), other combinations
HCPCS
No data
Clinical
Clinical Trials
1663 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I1014402432101
Healthy volunteers/patients35136
Essential hypertensionD000075222I10151310
Kidney diseasesD007674EFO_0003086N08336
Isolated systolic hypertensionD0000922441113
Type 2 diabetes mellitusD003924EFO_0001360E11123
Diabetes mellitusD003920EFO_0000400E08-E13123
Diabetic nephropathiesD003928EFO_000040133
Cardiovascular diseasesD002318EFO_0000319I98112
Renal insufficiencyD051437N19112
Show 8 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systolic murmursD054160R01.1112
Polycystic kidney diseasesD007690Q61.322
DyslipidemiasD05017111
Chronic renal insufficiencyD051436N1811
Chronic kidney failureD007676EFO_0003884N18.611
Disease progressionD01845011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.911
Insulin resistanceD007333EFO_0002614E88.81911
OverweightD050177E66.311
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver diseasesD008107EFO_0001421K70-K7711
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
Fatty liverD005234EFO_000393411
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.011
SepsisD018805EFO_0001420A41.911
NeoplasmsD009369C8011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAngiotensin ii
INNangiotensin ii
Description
Ile(5)-angiotensin II is an angiotensin II that acts on the central nervous system (PDB entry: 1N9V). It has a role as a human metabolite. It is a tautomer of an Ile(5)-angiotensin II dizwitterion.
Classification
Protein
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O
Identifiers
PDB
CAS-ID11128-99-7
RxCUI
ChEMBL IDCHEMBL408403
ChEBI ID2719
PubChem CID
DrugBank
UNII IDM089EFU921 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AGTR2
AGTR2
MAS1
MAS1
KCNK3
KCNK3
AGTR1
AGTR1
Organism
Homo sapiens
Gene name
AGTR2
Gene synonyms
NCBI Gene ID
Protein name
type-2 angiotensin II receptor
Protein synonyms
Angiotensin II type-2 receptor, AT2 receptor
Uniprot ID
Mouse ortholog
Agtr2 (11609)
type-2 angiotensin II receptor (P35374)
Variants
No data
Financial
Revenue by drug
$
£
Giapreza Innoviva
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 215,662 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
234 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use